Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
20
03
2021
accepted:
24
05
2021
revised:
19
05
2021
pubmed:
10
6
2021
medline:
18
3
2022
entrez:
9
6
2021
Statut:
ppublish
Résumé
Testicular Leydig cell tumor (LCT), the most common sex-cord stromal tumor in men, represents a small fraction of all testicular tumors (~1 to 3%). Although most testicular LCTs are indolent and cured by radical orchiectomy, 5-10% have aggressive biology and metastatic potential. In primary LCTs, large size, cytologic atypia, necrosis, increased mitotic activity, and vascular invasion have been associated with clinically aggressive tumors. From a molecular perspective, the characteristics of aggressive LCTs and the differences between aggressive and nonaggressive LCTs remain largely unexplored. This study compares the genomic landscape of aggressive and nonaggressive testicular LCTs. Twenty-six cases were analyzed using next-generation DNA sequencing (NGS) and immunohistochemistry. Cases were classified as aggressive LCT if they met published criteria for malignancy in primary (i.e., testicular) tumors or if they had pathology-proven metastatic disease; otherwise, cases were considered nonaggressive. This multi-institutional series included 18 aggressive LCTs (14 primary/testicular, 4 metastatic) and 8 nonaggressive LCTs. Two cases (2/26, 8%; both aggressive LCTs) failed sequencing and had negative (i.e., uninformative) FH immunohistochemistry results. One additional primary aggressive LCT failed sequencing but had informative FH immunohistochemistry results. Combined NGS and immunohistochemical analysis demonstrated FH inactivation in 5/26 cases (19%). In addition, NGS demonstrated CTNNB1 mutations or biallelic APC inactivation in 9/23 cases (39%), copy number changes without recurrent mutations in 6/23 (26%) cases, and no alterations in 4/23 cases (17%). CTNNB1 mutations were present in both aggressive and nonaggressive LCTs. In contrast, FH inactivation and multiple copy number changes were only identified in aggressive LCTs. In conclusion, three distinct subgroups of aggressive LCTs were characterized by FH inactivation, Wnt pathway activation, and copy number changes without recurrent mutations, respectively. Nuclear translocation of β-catenin and Wnt pathway activation appear to be early driver events that provide an environment conducive for progression to aggressive biology in a subset of LCTs.
Identifiants
pubmed: 34103665
doi: 10.1038/s41379-021-00845-3
pii: S0893-3952(22)00538-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1935-1946Informations de copyright
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Dilworth JP, Farrow GM, Oesterling JE. Non-germ cell tumors of testis. Urology. 1991;37:399–417.
doi: 10.1016/0090-4295(91)80100-L
Osbun N, Winters B, Holt SK, Schade GR, Lin DW, Wright JL. Characteristics of patients with Sertoli and Leydig cell testis neoplasms from a national population-based registry. Clin Genitourin Cancer. 2017;15:e263–66.
doi: 10.1016/j.clgc.2016.08.001
McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing incidence of testicular germ cell tumors among Black men in the United States. JCO. 2005;23:5757–61.
doi: 10.1200/JCO.2005.08.227
Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology. 2015;3:13–8.
doi: 10.1111/andr.288
Ghazarian AA, McGlynn KA. Increasing incidence of testicular germ cell tumors among racial/ethnic minorities in the United States. Cancer Epidemiol Biomark Prev. 2020;29:1237–45.
doi: 10.1158/1055-9965.EPI-20-0107
Emerson RE, Ulbright TM. Neoplasms of the testis. In: Chang L, MacLennan G, Bostwick D, editors. Urological surgical pathology. 4th ed. Philadelphia, PA: Elsevier; 2019. p. 800–7.
Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann K-P, Sulser T, et al. Risk factors and treatment outcomes of 1,375 patients with testicular Leydig cell tumors: analysis of published case series data. J Urol. 2020;203:949–56.
doi: 10.1097/JU.0000000000000705
Heer R, Jackson MJ, El-Sherif A, Thomas DJ. Twenty-nine Leydig cell tumors: histological features, outcomes and implications for management. Int J Urol. 2010;17:886–9.
doi: 10.1111/j.1442-2042.2010.02616.x
Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM. Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. Am J Surg Pathol. 1998;22:1361–7.
doi: 10.1097/00000478-199811000-00006
McCluggage WG, Shanks JH, Arthur K, Banerjee SS. Cellular proliferation and nuclear ploidy assessments augment established prognostic factors in predicting malignancy in testicular Leydig cell tumours. Histopathology. 1998;33:361–8.
doi: 10.1046/j.1365-2559.1998.00484.x
Colecchia M, Bertolotti A, Paolini B, Giunchi F, Necchi A, Paganoni AM, et al. The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification. Histopathology. 2021;78:290–9.
doi: 10.1111/his.14225
Carvajal-Carmona LG, Alam NA, Pollard PJ, Barclay E, Wortham N, Pignatelli M, et al. Adult Leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab. 2006;91:3071–5.
doi: 10.1210/jc.2006-0183
Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio J-A, Killian JK, et al. Genomic features of metastatic testicular sex cord stromal tumors. Eur Urol Focus. 2019;5:748–55.
doi: 10.1016/j.euf.2019.05.012
Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol. 1985;9:177–92.
doi: 10.1097/00000478-198503000-00002
Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med. 2017;141:751–8.
doi: 10.5858/arpa.2016-0527-OA
Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1:e87062.
doi: 10.1172/jci.insight.87062
Abo RP, Ducar M, Garcia EP, Thorner AR, Rojas-Rudilla V, Lin L, et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015;43:e19.
doi: 10.1093/nar/gku1211
Papke DJ, Nowak JA, Yurgelun MB, Frieden A, Srivastava A, Lindeman NI, et al. Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. Mod Pathol. 2018;31:1882–90.
doi: 10.1038/s41379-018-0091-x
Carmignani L, Salvioni R, Gadda F, Colecchia M, Gazzano G, Torelli T, et al. Long-term followup and clinical characteristics of testicular Leydig cell tumor: experience with 24 cases. J Urol. 2006;176:2040–3.
doi: 10.1016/j.juro.2006.07.005
Jou P, Maclennan GT. Leydig cell tumor of the testis. J Urol. 2009;181:2299–300.
doi: 10.1016/j.juro.2009.02.051
Banerji JS, Odem-Davis K, Wolff EM, Nichols CR, Porter CR. Patterns of care and survival outcomes for malignant sex cord stromal testicular cancer: results from the National Cancer Data Base. J Urol. 2016;196:1117–22.
doi: 10.1016/j.juro.2016.03.143
Liu G, Duranteau L, Carel JC, Monroe J, Doyle DA, Shenker A. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med. 1999;341:1731–6.
doi: 10.1056/NEJM199912023412304
Zhang C, Ulbright TM. Nuclear localization of β-catenin in sertoli cell tumors and other sex cord-stromal tumors of the testis: an immunohistochemical study of 87 cases. Am J Surg Pathol. 2015;39:1390–4.
doi: 10.1097/PAS.0000000000000455
Perrone F, Bertolotti A, Montemurro G, Paolini B, Pierotti MA, Colecchia M. Frequent mutation and nuclear localization of β-catenin in sertoli cell tumors of the testis. Am J Surg Pathol. 2014;38:66–71.
doi: 10.1097/PAS.0b013e31829cdbc6